Production (Stage)
Anavex Life Sciences Corp.
AVXL
$7.53
-$0.14-1.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.53M | 11.81M | 11.35M | 11.16M | 11.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.44M | 53.17M | 50.78M | 49.12M | 47.89M |
| Operating Income | -53.44M | -53.17M | -50.78M | -49.12M | -47.89M |
| Income Before Tax | -47.33M | -46.68M | -43.19M | -41.66M | -40.62M |
| Income Tax Expenses | -191.00K | -191.00K | -191.00K | -131.00K | -23.00K |
| Earnings from Continuing Operations | -47.14 | -46.49 | -43.00 | -41.53 | -40.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.14M | -46.49M | -43.00M | -41.53M | -40.59M |
| EBIT | -53.44M | -53.17M | -50.78M | -49.12M | -47.89M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.56 | -0.55 | -0.51 | -0.50 | -0.50 |
| Normalized Basic EPS | -0.35 | -0.35 | -0.32 | -0.31 | -0.31 |
| EPS Diluted | -0.56 | -0.55 | -0.51 | -0.50 | -0.50 |
| Normalized Diluted EPS | -0.35 | -0.35 | -0.32 | -0.31 | -0.31 |
| Average Basic Shares Outstanding | 339.21M | 336.60M | 333.87M | 331.05M | 327.39M |
| Average Diluted Shares Outstanding | 339.21M | 336.60M | 333.87M | 331.05M | 327.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |